Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
pharmaphorum3d
Merck bets on Inspirna’s colorectal cancer drug ompenaclid
The agreement gives Merck exclusive ex-US rights to ompenaclid – an oral inhibitor of the creatine transport channel SLC6A8 – as well as options to co-develop and co-promote the drug in the US ...
BMJ17d
Creatine and pregnancy outcomes, a prospective cohort study in low-risk pregnant women: study protocol
Primary outcome measures will include creatine, creatine kinase and associated metabolites in antenatal bloods and urine, cord bloods and placenta, along with molecular analysis of the creatine ...
Nature29d
Genetic testing in autism: how much is enough?
Purpose: To evaluate the yield of genetic testing in children with autism spectrum disorders. Methods: We performed a retrospective chart review of 71 unrelated patients with a diagnosis of an ...
jmg.bmj23d
Identification of pathogenic gene variants in small families with intellectually disabled siblings by exome sequencing
1 Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 2 Institute for Genetic and Metabolic Disease, Radboud University Nijmegen Medical Centre, ...
Frontiers27d
Review of electrophysiological models to study membrane potential changes in breast cancer cell transformation and tumor progression
The transformation of normal breast cells into cancerous cells is a complex process influenced by both genetic and microenvironmental factors. Recent studies highlight the significant role of membrane ...